Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 12.32%361.86M | 12.67%241.49M | 29.27%88.26M | 9.86%515.45M | 14.33%322.15M | 1.53%214.33M | 68.28M | 2.27%469.18M | 281.77M | -23.94%211.1M |
| Operating revenue | 12.32%361.86M | 12.67%241.49M | 29.27%88.26M | 9.86%515.45M | 14.33%322.15M | 1.53%214.33M | --68.28M | 2.27%469.18M | --281.77M | -23.94%211.1M |
| Other operating revenue | ---- | --0 | ---- | --0 | ---- | --0 | ---- | --0 | --0 | ---- |
| Total operating cost | 12.84%281.17M | 13.58%192M | 17.99%74.22M | 9.46%393.79M | 2.36%249.17M | 169.05M | 62.9M | 2.18%359.77M | 243.43M | |
| Operating cost | 12.51%200.1M | 16.77%138.84M | 24.75%47.62M | 8.64%287.42M | 6.18%177.85M | --118.9M | --38.17M | 4.55%264.57M | --167.5M | ---- |
| Operating tax surcharges | 7.19%3.09M | -23.32%1.54M | -40.57%542.49K | -17.57%3.74M | 5.70%2.88M | --2.01M | --912.86K | 50.45%4.53M | --2.72M | ---- |
| Operating expense | 9.80%20.36M | 7.11%12.72M | 2.17%6.11M | 6.96%26.45M | -8.25%18.54M | --11.87M | --5.98M | -14.78%24.73M | --20.21M | ---- |
| Administration expense | 14.95%38.62M | 16.11%26.37M | 18.96%13.44M | 13.82%49.12M | -2.46%33.59M | --22.71M | --11.3M | 5.93%43.15M | --34.44M | ---- |
| Financial expense | -2.98%-11.93M | -40.70%-7.07M | -7.63%-2.97M | -18.62%-9.68M | -181.68%-11.59M | ---5.02M | ---2.76M | -329.22%-8.16M | ---4.11M | ---- |
| -Interest expense (Financial expense) | -36.73%74.52K | -36.47%52.4K | -38.40%26.68K | -27.46%148.88K | -25.93%117.79K | --82.49K | --43.32K | -39.68%205.23K | --159.03K | ---- |
| -Interest Income (Financial expense) | -13.77%-11.06M | -20.57%-7.7M | -20.82%-4.01M | -37.18%-13.02M | -18.28%-9.72M | ---6.39M | ---3.32M | -205.63%-9.49M | ---8.22M | ---- |
| Research and development | 10.89%30.93M | 5.52%19.61M | 1.90%9.48M | 18.74%36.74M | 23.06%27.9M | --18.58M | --9.3M | 9.77%30.95M | --22.67M | ---- |
| Credit Impairment Loss | -3.99%-1.18M | 92.24%-54.34K | -111.45%-267.46K | -47.60%-9.74M | 76.28%-1.14M | ---700.35K | --2.34M | -27.96%-6.6M | ---4.8M | ---- |
| Asset Impairment Loss | 102.90%60.64K | 45.25%-784.29K | 351.67%196.23K | -0.09%-4.31M | 48.31%-2.09M | ---1.43M | ---77.97K | -5.97%-4.31M | ---4.05M | ---- |
| Other net revenue | 4,547.27%6.5M | 1,336.22%4.05M | -72.68%945.2K | -369.96%-9.99M | 106.02%139.88K | 282.11K | 3.46M | -153.17%-2.12M | -2.32M | 0 |
| Fair value change income | --224.76K | --144.93K | --9K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Invest income | --1.84M | --964.78K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other revenue | 64.91%5.56M | 56.56%3.78M | -16.19%1.01M | -53.73%4.06M | -48.32%3.37M | --2.41M | --1.2M | -35.20%8.78M | --6.53M | ---- |
| Operating profit | 19.24%87.19M | 17.50%53.54M | 69.73%14.99M | 4.08%111.67M | 103.02%73.12M | 47.95%45.57M | 8.83M | -3.05%107.29M | 36.02M | -56.30%30.8M |
| Add:Non operating Income | 264.24%10.48K | 18.29%3.4K | --3.38K | -9.28%67.13K | -96.11%2.88K | --2.88K | ---- | 90.02%73.99K | --73.99K | ---- |
| Less:Non operating expense | -94.72%2.06K | -93.88%2.06K | --2.06K | 126.32%51.44K | 156.06%39.07K | --33.7K | ---- | -95.84%22.73K | --15.26K | ---- |
| Total profit | 19.31%87.19M | 17.58%53.54M | 69.74%14.99M | 4.05%111.69M | 102.59%73.08M | 47.92%45.54M | 8.83M | -2.55%107.34M | 36.07M | -56.31%30.78M |
| Less:Income tax cost | 16.87%9.21M | 26.19%5.61M | 227.83%898.19K | -12.91%9.72M | 1,358.63%7.88M | --4.44M | --273.98K | -10.85%11.16M | --540.53K | ---- |
| Net profit | 19.60%77.98M | 16.65%47.94M | 64.68%14.09M | 6.02%101.96M | 83.48%65.2M | 42.47%41.1M | 8.56M | -1.49%96.18M | 35.53M | -53.32%28.85M |
| Net profit from continuing operation | 19.60%77.98M | 16.65%47.94M | 64.68%14.09M | 6.02%101.96M | 83.48%65.2M | --41.1M | --8.56M | -1.49%96.18M | --35.53M | ---- |
| Net profit of parent company owners | 19.60%77.98M | 16.65%47.94M | 64.68%14.09M | 6.02%101.96M | 83.48%65.2M | 42.47%41.1M | --8.56M | -1.49%96.18M | --35.53M | -53.32%28.85M |
| Earning per share | ||||||||||
| Basic earning per share | -10.30%1.324 | -12.51%0.8139 | 23.54%0.2393 | 3.15%2.2459 | 84.50%1.476 | --0.9303 | --0.1937 | -1.48%2.1773 | --0.8 | ---- |
| Diluted earning per share | -10.30%1.324 | -12.51%0.8139 | 23.54%0.2393 | 3.15%2.2459 | --1.476 | --0.9303 | --0.1937 | --2.1773 | ---- | ---- |
| Other composite income | 162.93%2.27M | 3,454.14%5.1M | 772.03%1.65M | -107.43%-649.88K | -158.33%-3.61M | 143.39K | -245.78K | 2,795.33%8.74M | 6.19M | |
| Other composite income of parent company owners | 162.93%2.27M | 3,454.14%5.1M | 772.03%1.65M | -107.43%-649.88K | -158.33%-3.61M | --143.39K | ---245.78K | 2,795.33%8.74M | --6.19M | ---- |
| Total composite income | 30.30%80.25M | 28.61%53.03M | 89.42%15.75M | -3.44%101.31M | 47.61%61.59M | 41.24M | 8.31M | 7.13%104.92M | 41.72M | |
| Total composite income of parent company owners | 30.30%80.25M | 28.61%53.03M | 89.42%15.75M | -3.44%101.31M | 47.61%61.59M | --41.24M | --8.31M | 7.13%104.92M | --41.72M | ---- |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Rong Cheng Certified Public Accountants (Special General Partnership) | -- | -- | -- | Rong Cheng Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.